Clinical trials showed that NeuroAiD™ helps in stroke recovery
NeuroAiD™ more than doubles chances of achieving independence
A review of all clinical trials assessing the benefits of NeuroAiD™ in recovering independence was published in 2013. I It showed that NeuroAiD™ increases by more than twice the chances of being independent and noted a trend towards more improvement in movement. Independence for a stroke victim is defined as being able to take care of oneself and speak freely.
Siddiqui et al, Cerebrovascular Diseases 2013
NeuroAiD™ improves activities of daily living
A double-blind, placebo-control clinical trial on 80 subjects showed better improvement in ability to perform activities of daily living at 3 months among NeuroAiD™ treated patients as compared to controls (Barthel Index improvement of 36 vs 29 points; p<0.001).
Shahripour et al European Journal of Internal Medicine 2011
Improving Motor Recovery
A study of 150 subjects recruited between 1 week and 3 months after stroke onset received 3 months of treatment. Motor recovery was assessed by Fugl-Meyer motor assessment scale (maximum score 100 points) every month for 3 months. This study showed that the motor recovery of patients on NeuroAiD™ was significantly much more than patients on placebo, and this difference was seen as early as 4 weeks from start of treatment and persists up to 3 months..
Harandi et al Stroke Research and Treatment 2011
NeuroAiD™ reduces early recurrence of stroke, heart attack and deaths by 50% after a stroke
A study was performed to investigate the effect of NeuroAiD™ on the occurrence of early vascular events, defined as a composite of recurrent stroke, acute coronary syndrome, and vascular death within 3 months after stroke onset.
A statistically significant reduction in the risk of vascular events and/or vascular death by half was observed in the first three months after a stroke: occurred in 47 (4.3%) patients over the 3-month follow-up period, with 16 (2.9%) patients in the NeuroAiD™ group and 31 (5.6%) in the placebo group. It corresponds to 27 patients avoiding the occurrence of early vascular events per 1000 patients treated for 3 months. The benefit is in addition to the benefits gained from secondary prevention standard treatment. The reduction was seen as early as the first two weeks after initiation of treatment.
There was no increase in bleeding and non-vascular death, confirming the excellent safety profile of NeuroAiD ™. This finding is consistent with the pleotropic mechanisms of action of NeuroAiD™ including its effect on ATP-sensitive potassium channel and its potential role in ischemic preconditioning.
Effects on other brain functions
NeuroAiD™ supports recovery of visual deficits
A study of 40 patients with pure homonymous hemianopsia from ischemic stroke, recruited within one week of onset and treated with either NeuroAiD™ or piracetam for 3 months, showed that patients on NeuroAiD™ gained back more of their visual field at 3 months compared to control.
Ghandehari et al, Neural Regeneration Research 2011
A case series published in European Neurology reported 10 cases of patients, from Mount Alvernia Hospital in Singapore, who received 2 to 3 months treatment of NeuroAiD™ after a stroke. Treatment was initiated between one week and six months post-stroke and given as an add-on medication.
The cases were a mixture of anterior and posterior circulation infarction with motor, sensory, balance,vision, and/or speech deficits.
All cases reported improvements:
- 6 cases of full recovery
- 2 cases of good recovery
- 1 case of moderate recovery
- 1 case of only minor recovery
Significant improvements were recorded in speech and visual functions, aside from motor and balance. Remarkably, three patients who started NeuroAiD™ treatment at a later stage of stroke recovery (i.e. 1 to 6 months after the stroke and recovery has reached a plateau) experienced significant recovery.